Status:
COMPLETED
Escalated Dose of Irinotecan in mCRC
Lead Sponsor:
Jaw-Yuan Wang, MD, PhD
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
Metastatic diseases were found in 20-25% of patients with initial diagnosis of colorectal cancer and developed in up to 50% of patients. Owing to limited post-treatment response of 5-fluorouracil (5-F...
Detailed Description
Control group: Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), LV (400 mg/m2 IV infusion over 2 hour...
Eligibility Criteria
Inclusion
- 20 y/o ≦ Age ≦ 80y/o
- Either metachronous or synchronous mCRC can be enrolled
- Female patients need not ready to be pregnant or breastfeeding
- No major underlying diseases (such as cardiovascular, cerebrovascular, malignant hypertension, kidney, liver and other major diseases)
- mCRC be proven by pathologists or radiologists
- Subjects are willing to sign an inform consent form
Exclusion
- Patients who do not meet the including criteria or unwilling to participate
Key Trial Info
Start Date :
August 13 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2017
Estimated Enrollment :
213 Patients enrolled
Trial Details
Trial ID
NCT02256800
Start Date
August 13 2014
End Date
November 30 2017
Last Update
November 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chung-Ho Memorial Hospital, Kaohsiung Medical University:
Kaohsiung City, Taiwan, 807